Are complications of implantable defibrillators under-estimated and benefits over-estimated?

Europace

Volumn 11, Issue 9, 2009, Pages 1129-1133

  Brignole, Michele ^a  

^a DEPARTMENT OF CARDIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARRHYTHMOGENESIS; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DEFIBRILLATOR; DEVICE INFECTION; DEVICE THERAPY; EDITORIAL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; MORTALITY; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SUDDEN DEATH; SURVIVAL RATE; SYSTOLIC DYSFUNCTION;

AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; GUIDELINE ADHERENCE; HUMANS; ITALY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70349437069     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup174     Document Type: Editorial

References (26)

1. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007;147:251-262 (Pubitemid 351664582)
2. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD et al. The frequency and incremental cost of major complications among Medicare ben-eficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 2006; 47 :2493-2497
3. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52;1111-1121
4. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 2002;105: 589-594
5. Mark D, Anstrom K, Sun J, Clapp-Channing N, Tsiatis A, Davidson-Ray L et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008;359:999-1008.
6. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237
7. Poole J, Johnson G, Hellkamp A, Anderson J, Callans D, Raitt M et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-1017
8. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357-1365
9. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of .10 years. Circulation 2007;115:2474-2480
10. Ellis C, Rottman J. Increased rate of subacute lead complications with small-caliber implantable-defibrillator leads. Heart Rhythm 2009;6:619-624
11. Maisel WH. Semper Fidelis - consumer protection for patients with implanted medical devices. N Engl J Med 2008;358:985-987
12. Maisel WH, Sweeney MO, Stevenson WG, Ellison KE, Epstein LM. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. J Am Med Assoc 2001;286:793-799
13. Hauser RG, Kallinen L. Deaths associated with implantable cardioverter defibril-lator failure and deactivation reported in the United States Food and Drug Administration Manufacturer and User Facility Device Experience Database. Heart Rhythm 2004;1:399-405.
14. Epstein A, DiMarco J, Ellenbogen K, Estes Mark NA III, Freedman R, Gettes L et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm. J Am Coll Cardiol 2008;51;e1-e62.
15. Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-2158
16. Proclemer A, Ghidina M, Gregori D, Facchin D, Rebellato L, Fioretti P et al. Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-2007. Europace 2009;11:465-475
17. Proclemer A, Facchin D, Brignole M, Castro A, Menozzi C, Villani GQ et al. Characteristics of first ICD implants in a chohrt of 825 consecutive patients: preliminary data from the SAFE-ICD study. In Proceedings of XIII International Symposium on Progress in Clinical Pacing, Rome, 2-5 December 2008 (abstract).
18. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150
19. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-2488
20. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883
21. Chow T, Kereiakes D, Onufer J, Woelfel A, Gursoy S, Peterson B et al. Does microvolt t-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) Trial. J Am Coll Cardiol 2008;52;1607-1615
22. Moss AJ, Greenberg H, Case RB, Brown MW, Lin AC, Andrews ML, Burke M. Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-3765
23. Goldenberg I, Vyas A, Hall J, Moss A, Wang H, He H et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-296
24. Myerburg R. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med 2008;359:2245-2253
25. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. J Am Coll Cardiol 2008;52:1179-1199
26. Costantini O, Hohnloser S, Kirk M, Lerman B, Baker J II, Sethuraman B et al. The ABCD (Alternans Before Cardioverter Defibrillator) trial: strategies using t-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol 2009;53:471-479